Inotek Considers Its Options After Another Glaucoma Failure
The eye disease company faces an uncertain future after its only product, trabodenoson, failed in another study in glaucoma.
The eye disease company faces an uncertain future after its only product, trabodenoson, failed in another study in glaucoma.